REGENXBIO Inc.
RGNXNasdaq
$9.89
↓ -11.7%Jul 17 close · end-of-day
Price
1Y↑ +16.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$518.5M
Enterprise Value
$368.0M
P/E
—
P/S
5.9
P/B
24.6
EV/EBITDA
—
PEG
—
FCF Yield
-45.6%
Dividend Yield
—
Revenue (TTM)
$87.8M
Net Income (TTM)
-$290.0M
Free Cash Flow (TTM)
-$236.4M
Gross Margin
—
Operating Margin
-292.3%
Net Margin
-330.2%
ROE
-1375.6%
ROIC
—
Debt / Equity
—
Net Cash
$150.5M
Return 1Y
+13.8%
Company profile
REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
- CEO
- Kenneth T. Mills
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 370
- Headquarters
- Maryland
- Website
- regenxbio.com
Management & directors
- Pakola SteveChief Medical Officer
- Simpson CurranChief Executive Officer
- Christmas Patrick J.Chief Strategy & Legal Officer
- Chan MitchellChief Financial Officer
- Malzahn CraigChief Technology Officer
Roles derived from SEC Form 4 filings.
Earnings
RGNX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.4M↓ -92.8%
Diluted EPS-$1.72↓ -1533.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$119.2M | $160.0M | -$262.9M | -$268.1M | -$233.3M | -$161.2M |
| Net income | -$111.3M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
| Diluted EPS | -$2.98 | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 |
| Operating cash flow | -$54.1M | $218.9M | -$207.5M | -$218.4M | -$173.1M | -$124.0M |
| Free cash flow | -$80.9M | $134.7M | -$238.2M | -$228.4M | -$175.6M | -$126.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -77.1% | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Net margin | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.3M | $24.2M | $21.2M | $89.0M | $21.4M | $29.7M | $30.3M | $6.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$56.0M | -$62.1M | -$51.4M | $12.1M | -$63.3M | -$52.4M | -$57.6M | -$83.4M |
| Net income | -$53.0M | -$59.6M | -$51.2M | $6.1M | -$70.9M | -$61.9M | -$67.1M | -$90.1M |
| Diluted EPS | -$1.05 | -$1.17 | -$0.99 | $0.12 | -$1.38 | -$1.20 | -$1.30 | -$1.72 |
| Operating cash flow | -$45.5M | -$40.5M | -$31.6M | $33.6M | -$49.3M | -$56.0M | -$52.3M | -$76.2M |
| Free cash flow | -$46.0M | -$40.9M | -$32.7M | $32.6M | -$49.7M | -$56.5M | -$52.8M | -$77.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -251.3% | -256.6% | -242.1% | 13.6% | -296.3% | -176.3% | -190.0% | -1304.0% |
| Net margin | -237.7% | -246.3% | -241.3% | 6.8% | -331.8% | -208.3% | -221.3% | -1408.6% |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | PAKOLA STEVE· Chief Medical Officer | Sale | 2,161 | $13.64 | $29,476.04 | filing |
| 2026-07-02 | PAKOLA STEVE· Chief Medical Officer | Option exercise | 2,161 | $7.86 | $16,985.46 | filing |
| 2026-07-01 | PAKOLA STEVE· Chief Medical Officer | Sale | 36,725 | $12.86 | $472,283.50 | filing |
| 2026-07-01 | PAKOLA STEVE· Chief Medical Officer | Option exercise | 36,725 | $7.86 | $288,658.50 | filing |
| 2026-07-01 | Simpson Curran· Chief Executive Officer | Tax withholding | 6,818 | $13.09 | $89,247.62 | filing |
| 2026-06-30 | Simpson Curran· Chief Executive Officer | Award | 1,453 | $10.18 | $14,791.54 | filing |
| 2026-06-29 | PAKOLA STEVE· Chief Medical Officer | Sale | 19,608 | $11.04 | $216,472.32 | filing |
| 2026-05-29 | Fox Allan M. | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | Bennett Jean | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | Glucksmann Alexandra | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | Tasse Daniel | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | STUMP DAVID C | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | Zachary Jennifer | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | Mills Kenneth T. | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | MIGAUSKY GEORGE V | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-29 | KARABELAS ARGERIS N | Award | 9,807 | $0.00 | $0.00 | filing |
| 2026-05-11 | PAKOLA STEVE· Chief Medical Officer | Sale | 15,309 | $11.02 | $168,705.18 | filing |
| 2026-03-10 | PAKOLA STEVE· Chief Medical Officer | Sale | 5,124 | $10.35 | $53,033.40 | filing |
| 2026-02-01 | PAKOLA STEVE· Chief Medical Officer | Tax withholding | 5,267 | $11.16 | $58,779.72 | filing |
| 2026-02-01 | Christmas Patrick J.· Chief Strategy & Legal Officer | Tax withholding | 4,700 | $11.16 | $52,452.00 | filing |
| 2026-01-27 | Mills Kenneth T. | Tax withholding | 221,753 | $13.41 | $3.0M | filing |
| 2026-01-27 | Mills Kenneth T. | Option exercise | 225,000 | $13.09 | $2.9M | filing |
| 2026-01-06 | PAKOLA STEVE· Chief Medical Officer | Award | 65,847 | $0.00 | $0.00 | filing |
| 2026-01-06 | Malzahn Craig· Chief Technology Officer | Award | 65,847 | $0.00 | $0.00 | filing |
| 2026-01-06 | Simpson Curran· Chief Executive Officer | Award | 144,864 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.